Drug Profile


Alternative Names: BAY-864875; Gadavist; Gadobutrol injection for MRI of CNS - Bayer; Gadovist; Gadovist 1.0; Gd-DO3A-butriol; SHL 562

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer Schering Pharma
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Gadolinium-containing contrast agents; Organometallic compounds; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Vascular disorders

Most Recent Events

  • 01 Nov 2016 Bayer completes the GadaCAD 2 trial in Vascular disorders in USA, Australia, Canada and Singapore (NCT01890434)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Vascular-disorders(Diagnosis, In infants, In neonates) in Canada (IV, Injection)
  • 02 May 2016 Product launched for use with magnetic resonance angiography (MRA) to evaluate known or suspected supra-aortic or renal artery disease in 2016, in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top